Gennari A et al. – Longer first-line chemotherapy duration is associated with marginally longer OS and a substantially longer PFS.

• Searched literature databases to identify randomized controlled trials that compared different chemotherapy durations in first-line treatment of MBC
• Only trials with unconfounded comparisons of additional cycles of chemotherapy included
• Main outcome measures for this analysis OS and PFS
• Published data from retrieved studies analyzed according to standard meta-analytic techniques

• 11 randomized clinical trials including 2,269 patients
• Longer first-line chemotherapy duration resulted in significantly improved OS (HR 0.91; 95% CI, 0.84 to 0.99) and PFS (HR, 0.64; 95% CI, 0.55 to 0.76)
• No differences in effects on either OS or PFS between subgroups defined by time of random assignment, study design, number of chemotherapy cycles in control arm or concomitant endocrine therapy